Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 0.98 |
| ▸ | KDR | P35968 | 3/20 | 0.98 |
| ▸ | BRAF | P15056 | 2/20 | 0.98 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.98 |
| ▸ | FLT4 | P35916 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.98 |
| ▸ | STK17B | O94768 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.98 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL28098790 | 1.00 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL465143 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351046 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351336 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL7866 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 0.99 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL30887946 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28097850 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL11776 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29371159 | 0.98 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103319422-B | A kind of Gefitinib crystal formation and preparation method thereof | Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. of CSPC Group (CN) | 2016-05-04 | — | — | CN | disclosed |
| CN-103319422-A | New gefitinib crystal form and preparation method thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-09-25 | — | — | CN | disclosed |
| US-20100137304-A1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-1480650-B1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | ASTRAZENECA AB (SE) | 2010-04-28 | — | — | EP | disclosed |
| US-7612077-B2 | Crystalline forms of the anti-cancer compound ZD1839 | ASTRAZENECA AB (SE) | 2009-11-03 | — | — | US | disclosed |
| US-20050209229-A1 | Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| EP-1480650-A1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | AstraZeneca AB (SE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003072108-A1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209229-A1 | Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib | KRAS, IWS1, JAK2 | EGFR 14/4885KDR 255/4885BRAF 7/4885 |
| US-20100137304-A1 | NOVEL CRYSTALLINE FORMS OF THE ANTI-CANCER COMPOUND ZD1839 | BCL9, CCND1, BCL9L | EGFR 2807/4885KDR 3652/4885BRAF 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.